TAKTakeda Pharmaceutical Company Limited

$18.73+24% 1Y

What is the market doing?

Mixed

No clear lean: nothing decisive, though in an uptrend.

1 good, 2 neutral
TrendUptrendderived · Oct 9, 2026

In an uptrend, above its rising 50- and 200-day averages. Price is +9% vs its 200-day average.

Insider conviction−$13.1M (90 days to Oct 8, 2026)SEC EDGAR · Oct 8, 2026

Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).

Short interest0.2% of sharesFINRA · Sep 15, 2026

A token position, settled Sep 15, 2026, a few days of normal trading to cover. Up 2.8% since the previous count, unchanged over three months.

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How TAK is trading

Takeda Pharmaceutical Company Limited is +24% over the past year while the S&P 500 is +18%: 6.1 points ahead of the market.

+24%

1-year return · S&P 500 +18%

vs 200-day average
+9.5%

vs 200-day average · close to trend

RSI (14)
47

RSI (14) · neutral

Below its 52-week high
1.7%

Below its 52-week high

Sep 18, 2024$12.60 – $19.05 · dashed line: 200-day averageOct 9, 2026
Details›
Last close2026-10-09
$18.73
1 monthS&P 500 +2.7%
+3.4%
1 yearS&P 500 +18%
+24%
5 yearsS&P 500 +88%
+19%
vs 50-day average$18.12
+3.4%
52-week high
$19.05
52-week low
$13.23
Annualised volatility
21%
Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
−$11M
Calendar-year price return
YearReturn
2026 (year to date)+20%
2025+20%
2024−3.1%
2023−8.5%
2022+14%
2021−25%
2020−7.8%
2019+17%
2018−41%
2017+37%
Average return by calendar month, 2016–2026
MonthYearsPositiveAverage
Jan108 of 10+3.9%
Feb105 of 10+1.1%
Mar105 of 10−1.1%
Apr105 of 10−1.9%
May104 of 10−0.65%
Jun103 of 10−0.87%
Jul117 of 11+1.8%
Aug117 of 11+1.2%
Sep115 of 11−0.13%
Oct114 of 11−4.2%
Nov105 of 10+2.3%
Dec107 of 10+0.62%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.